Treatment | Page 404 of 465

Diabetes :: Exubera – Inhaled Insulin Combination for Treatment of Diabetes

There is a new, potential alternative for many of the more than 5 million Americans who take insulin injections, with the Food and Drug Administration’s approval today of the first ever inhaled insulin. Exubera, an inhaled powder form of recombinant human insulin (rDNA) for the treatment of adult patients with type 1 and type 2 diabetes, is the first new insulin delivery option introduced since the discovery of insulin in the 1920s.

Diabetes :: Weight Loss Improves Bladder Control in Women with Prediabetes

Losing a modest amount of weight through dietary changes and increased physical activity reduces the occurrence of urinary incontinence (UI) in women with prediabetes, a condition in which blood glucose levels are higher than normal but not yet diabetic. This finding comes from a new study, published in the February issue of Diabetes Care, of women who participated in the Diabetes Prevention Program (DPP), a landmark clinical study funded by the National Institutes of Health (NIH).

Depression :: Team approach to treat depression in elderly people

A “team approach” to treat depression in elderly people produces effective, lasting results, a new U.S. study finds.

Cancer :: Sutent, sunitinib for Gastrointestinal – Stomach Cancer, Kidney Cancer

The Food and Drug Administration (FDA) announced approval of Sutent (sunitinib), a new targeted anti-cancer treatment for patients with gastrointestinal stromal tumors (GIST), a rare stomach cancer, and advanced kidney cancer. This action marks the first time the agency has approved a new oncology product for two indications simultaneously.

Influenza :: Fraudulent, unapproved influenza related products

FDA considers the sale of unlicensed or unapproved influenza – related products as a potentially significant threat to the public health and is taking measures to protect consumers from fraudulent products that claim to prevent or treat seasonal or avian (bird) influenza in people.

Polycystic Kidney Disease :: HALT-PKD Treatment Trials

The National Institutes of Health (NIH) and the PKD Foundation have launched two treatment trials for autosomal dominant polycystic kidney disease (ADPKD). The common inherited disorder is characterized by cysts in the kidneys and other organs, high blood pressure, and aneurysms (bulges in blood vessels, which may burst) in the brain.

Heart Disease :: Dietary supplement may harm heart patients

Heart attack patients should avoid the dietary supplement L-arginine based on a study that was scuttled after six volunteers taking the over-the-counter supplement d i ed, researchers.

Cystic Fibrosis :: First dry powder inhalation antibiotic for cystic fibrosis

Forest Laboratories, having developed what it believes is the world?s first dry powder inhalation system for antibiotics, is now conducting phase III trials on a new dry powder antibiotic formulation which promises to change the lives of cystic fibrosis sufferers by drastically reducing the daily treatment time.

Diabetes :: Generex developing new chewing gum for diabetes

Buccal drug delivery pioneer, Generex, is expanding its diabetes treatment pipeline to include a new metformin chewing gum that aims to avoid the significant adverse gastrointestinal side-effects often accompanying the use of metformin tablets.

Diet :: Diet drug pill may pose a risk – Xenical – orlistat

GlaxoSmithKline PLC’s Xenical diet pill may pose a risk if people take it without a prescription or a doctor’s supervision, federal regulators said.